

**Decreasing Cardiovascular Risk for Patients with Persistent  
Hypercholesterolemia —  
An Animated Whiteboard View  
TOOLKIT**

**Websites and Additional Reading**

CDC. Cholesterol.	<a href="https://www.cdc.gov/cholesterol/facts.htm">https://www.cdc.gov/cholesterol/facts.htm</a>
NIH. US National Library of Medicine. Genetics Home Reference. Hypercholesterolemia.	<a href="https://ghr.nlm.nih.gov/condition/hypercholesterolemia">https://ghr.nlm.nih.gov/condition/hypercholesterolemia</a>
NIH. US National Library of Medicine. Medline Plus. High Blood Cholesterol Levels.	<a href="https://medlineplus.gov/ency/article/000403.htm">https://medlineplus.gov/ency/article/000403.htm</a>
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (Grundy SM, et al. <i>J Am Coll Cardiol.</i> 2019;73(24):e285-e350)	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30423393">https://www.ncbi.nlm.nih.gov/pubmed/30423393</a>
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. (Bittner VA, Giugliano RP, Brinton EA, Guyton JR. <i>J Clin Lipidol.</i> 2018;12:835-843)	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30055750">https://www.ncbi.nlm.nih.gov/pubmed/30055750</a>
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. (Dixon DJ, et al. <i>Curr Atheroscler Rep.</i> 2019;21(5):16)	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30877491">https://www.ncbi.nlm.nih.gov/pubmed/30877491</a>
Evolocumab and clinical outcomes in patients with cardiovascular disease. (Sabatine MS, et al. <i>N Engl J Med.</i> 2017;376:1713-1722)	<a href="https://www.ncbi.nlm.nih.gov/pubmed/28304224">https://www.ncbi.nlm.nih.gov/pubmed/28304224</a>
Alirocumab and cardiovascular outcomes after acute coronary syndrome. (Schwartz GG, et al. <i>N Engl J Med.</i> 2018;379:2097-2107)	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30403574">https://www.ncbi.nlm.nih.gov/pubmed/30403574</a>

Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.

(Sampson UK, Fazio S, Linton MF. *Curr Atheroscler Rep.* 2012;14:1-10)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697085/>

### ***Selected Ongoing Clinical Trials***

<b>Resource</b>	<b>Address</b>
<b>An Extension Trial of Inclisiran Compared to Evolocumab in Participants with Cardiovascular Disease and High Cholesterol NCT03060577</b>	<a href="https://clinicaltrials.gov/ct2/show/NCT03060577?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;rank=7">https://clinicaltrials.gov/ct2/show/NCT03060577?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;rank=7</a>
<b>Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia NCT03175367</b>	<a href="https://clinicaltrials.gov/ct2/show/NCT03175367?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;draw=2&amp;rank=12">https://clinicaltrials.gov/ct2/show/NCT03175367?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;draw=2&amp;rank=12</a>
<b>Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk Open-label Extension (FOURIER OLE) NCT02867813</b>	<a href="https://clinicaltrials.gov/ct2/show/NCT02867813?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;draw=1&amp;rank=19">https://clinicaltrials.gov/ct2/show/NCT02867813?term=pcsk9&amp;recrs=ad&amp;cond=hypercholesterolemia&amp;draw=1&amp;rank=19</a>
<b>Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo NCT02957682</b>	<a href="https://clinicaltrials.gov/ct2/show/NCT02957682?term=alirocumab&amp;recrs=abd&amp;cond=hypercholesterolemia&amp;rank=4">https://clinicaltrials.gov/ct2/show/NCT02957682?term=alirocumab&amp;recrs=abd&amp;cond=hypercholesterolemia&amp;rank=4</a>

### ***Resources for Clinicians and Patients***

<b>American College of Cardiology</b>	<a href="https://www.acc.org/search?q=Hypercholesterolemia&amp;sort=relevancy">https://www.acc.org/search?q=Hypercholesterolemia&amp;sort=relevancy</a>
<b>American Heart Association. Prevention and Treatment of High Cholesterol (Hyperlipidemia).</b>	<a href="https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia">https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia</a>
<b>CDC. Cholesterol Patient Education Handouts.</b>	<a href="https://www.cdc.gov/cholesterol/materials_for_patients.htm">https://www.cdc.gov/cholesterol/materials_for_patients.htm</a>
<b>NIH. National Heart, Lung, and Blood Institute. High Blood Cholesterol.</b>	<a href="https://www.nhlbi.nih.gov/health-topics/high-blood-cholesterol">https://www.nhlbi.nih.gov/health-topics/high-blood-cholesterol</a>

**National Lipid Association (NLA). An educational booklet for patients with familial hypercholesterolemia.**

<http://nlaresourcecenter.lipidjournal.com/Content/PDFs/FA-Patient-Book-English.pdf>